Premium
Rimantadine pharmacokinetics in healthy subjects and patients with end‐stage renal failure
Author(s) -
Capparelli Edmund V,
Stevens Robert C,
Chow Moses S S,
Izard Mark,
Wills Robert J
Publication year - 1988
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1988.69
Subject(s) - rimantadine , pharmacokinetics , medicine , volume of distribution , hemodialysis , end stage renal disease , urine , population , dialysis , amantadine , pharmacology , immunology , environmental health , influenza a virus , virus
The single‐dose (two 100 mg doses) pharmacokinetics of rimantadine hydrochloride were compared in eight patients with end‐stage renal disease who were on hemodialysis and seven age‐matched healthy subjects. Plasma and urine rimantadine concentrations were determined by a GC/MS method. The plasma half‐life (43.6 vs 27.5 hours) and AUC (9.9 ± 2.1 vs 6.0 ± 1.6 μg · hr/ml) were significantly (p < 0.05) increased in the patient population. No significant differences were noted in the maximum rimantidine concentration, time of maximum concentration, or apparent volume of distribution. Urinary excretion of unchanged rimantadine accounted for 16% of the dose in the healthy subjects. Hemodialysis did not appreciably remove rimantadine. These findings suggest that rimantadine dosage may need to be reduced in patients with end‐stage renal disease but supplemental doses on dialysis days are not required. Clinical Pharmacology and Therapeutics (1988) 43, 536–541; doi: 10.1038/clpt.1988.69